.png)
Agenzia Italiana del Farmaco
Direct communication with healthcare professionals on CAR-T anti-CD19 o anti-BCMA - Direct communication with healthcare professionals on CAR-T anti-CD19 o anti-BCMA
Direct communication with healthcare professionals on CAR-T anti-CD19 o anti-BCMA
Secondary malignancies of T-cell origin, including chimeric antigen receptor (CAR)-positive malignancies, have been reported within weeks and up to several years following treatment of haematological malignancies with a BCMA- or CD19-directed CAR T-cell therapy (Abecma, Breyanzi, Carvykti, Kymriah, Tecartus and Yescarta).
Patients should be monitored life-long for secondary malignancies.
Published on: 18 July 2024
